Manual coverTreatment training for advocates

6 HIV and pregnancy

6.8 ARVs in pregnancy: resistance and adherence

21 July 2009

Resistance

Some strategies to reduce mother-to-child transmission can lead easily to resistance. Using only 1 drug (monotherapy) or 2 drugs (dual therapy) is not as good as 3+ drugs (combination therapy).

Of monotherapy and dual therapy strategies, AZT used alone is less likely to lead to resistance than nevirapine alone or AZT + 3TC.

Resistance can also develop on combination therapy when a person’s viral load is over 50 copies/mL.

It is also possible to transmit resistant virus. The outlook for a baby born with resistant HIV is very poor. Their HIV will be much harder to treat.

Section 3: Resistance

Adherence

It is easy for a mother to forget her own health after the baby is born. For mothers taking HIV treatment, adherence is critical.

Missing dose, or taking them late, increases the chance of resistance.

  • Many women have excellent adherence when pregnant, but find this hard after the baby is born.
  • Many mothers find the best way to remember to take their own ARVs is to link this to when they give the new baby his or her treatment.

Section 3: Adherence – and why it is so important


HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info